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Aim: To explore the added value of diabetes-related genetic risk scores (GRSs) to
readily available clinical variables in the prediction of glycated haemoglobin (HbA1c)
levels after initiation of glucose-regulating drugs.
Materials and methods:We conducted a cohort study in people with type 2 diabetes
(T2DM) from the Groningen Initiative to Analyse Type 2 Diabetes Treatment
(GIANTT) database who initiated metformin (MET) or sulphonylurea derivatives (SUs)
and for whom blood samples were genotyped. The primary outcome was HbA1c
level at 6 months, adjusted for baseline HbA1c. GRSs were based on single nucleo-
tide polymorphisms linked to insulin sensitivity, β-cell activity, and T2DM risk in gen-
eral. Associations were analysed using multiple linear regression to assess whether
adding the GRSs increased the explained variance in a prediction model that included
age, gender, diabetes duration and cardio-metabolic biomarkers.
Results: We included 282 patients initiating MET and 89 patients initiating SUs. In
the MET prediction model, diabetes duration of >3 months when starting MET was
associated with 2.7-mmol/mol higher HbA1c level. For SUs, no significant clinical
predictors were identified. Addition of the GRS linked to insulin sensitivity (for MET),
β-cell activity (for SUs) and T2DM risk (for both) to the models did not improve the
explained variance significantly (22% without vs. 22% with GRS) for the MET and
(14% without vs. 14% with GRS) for the SUs model, respectively.
Conclusion: This study did not indicate a significant effect of GRS related to T2DM
in general or to the drugs' mechanism of action for prediction of inter-individual
HbA1c variability in the short term after initiation of MET or SU therapy.
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1 | INTRODUCTION
Metformin (MET) and sulphonylurea derivatives (SUs) are effective
drugs for the treatment of hyperglycaemia in people with type 2 dia-
betes mellitus (T2DM). Previous studies have shown that the inter-
individual variability in treatment response to these drugs is high.1-3
As the general aim of T2DM drug therapy is to prevent diabetes-
related complications, it is important to obtain more insight into
potential predictors of treatment response in the disease's initial
stages in order to tailor therapy optimally.
In a previous systematic review, we assessed whether clinical vari-
ables could predict the initial glycated haemoglobin (HbA1c) response
to these drugs. The review showed that diabetes duration was the only
consistent predictor of response across studies, with early treatment
initiation in people with short diabetes duration being associated with
better treatment response.4 In addition to clinical variables, the influ-
ence of a person's genetic makeup on MET and SU treatment response
has been explored and systematically reviewed with an emphasis on
OCT genes, genes for encoding additional proteins associated with
AMP-activated protein kinase-dependent inhibition of gluconeogenesis,
SLC47A1 and A2, PMAT, ATM, IRS1, NOS1AP, KCNJ11, ABCC8, CYP2C9
and TCF7L2.5-8 Unfortunately, to date, the clinical applicability of
genotyping prior to drug treatment has been limited, because the effect
of the genetic variants on treatment response has been determined for
specific variants and not in an integrated way.9,10
A previous clinical study assessed the impact of genetic constitution
on diabetes progression. This resulted in the indentification of 65 risk
genes for T2DM, with clusters associated with β-cell activity and insulin
sensitivity.11 Because these risk genes drive disease progression in the
early stage of the disease, we hypothesized that, in addition to readily
available clinical predictors, these genes might also play a role in
predicting the initial treatment response. In contrast to investigating
the impact of genetic makeup from the perspective of the drugs used,
we approached the variability in response to MET and SUs from the
perspective of the genetic makeup involved in progression of T2DM.
The aim of the present study, therefore, was to determine the
added value of (a) clusters of T2DM-related genetic risk scores (GRSs)
related to β-cell activity (specifically in the case of SUs) and insulin sen-
sitivity (specifically in the case of MET), and (b) general GRSs for T2DM
in predicting HbA1c levels after treatment initiation of MET and SUs.
2 | PATIENTS AND METHODS
2.1 | Study design and population
We performed an observational inception cohort study predicting
HbA1c levels after treatment initiation among people with T2DM
included in the Groningen Initiative to Analyse Type 2 Diabetes Treat-
ment (GIANTT) project. The GIANTT database consists of prescription
data, comorbidity and clinical outcome data, routine laboratory test
results, and physical examinations extracted anonymously from elec-
tronic medical records.12 The cohort is predominantly of European
ancestry. The database includes people with a diagnosis of T2DM as
confirmed by their general practitioner. Based on the research code of
conduct in the Netherlands, ethics committee approval is not required
for research using such anonymous medical record data.
A subset of people with T2DM in the GIANTT database partici-
pated in PROVALID, an international cohort study on the incidence and
prevalence of kidney disease in primary diabetes care.13 The
PROVALID study was approved by the local Medical Ethics Committee
of the University Medical Centre of Groningen, and informed consent
was obtained from each participant for the use of genetic samples
before any study-specific procedures commenced (study approval ref-
erence number: NL35350.042.11, METC number 2011.297).
In the present study, we determined two sub-cohorts: a MET and
an SU cohort. For these cohorts, the index date was defined as the
date of the first MET or SU prescription, respectively.
In the MET cohort, the inclusion criteria were: (a) receiving MET
as first-line glucose-lowering drug; (b) registration in the GIANTT
database and receiving no glucose-lowering medication for at least
1 year before the index date; and (c) at least two prescriptions of MET
and exposure to MET at least until 30 days after the start of the sec-
ond prescription.
In the SU cohort, the inclusion criteria were receiving an SU as
first glucose-lowering drug (SU-only) or receiving add-on SU while on
a stable MET dose in the previous 6 months (SU-combi). Both SU-only
participants and SU-combi participants had to be prescribed at least
two prescriptions of an SU and exposed to an SU at least until 30 days
after the second prescription. In addition, people receiving SU-only
had to be registered in the GIANTT database and have received no
glucose-lowering drug for at least a year before the index date. This
implies that people who started on MET and reached a stable MET
dose after which an SU was added could be included in the MET
cohort for the first period and in the SU cohort for the second period.
In both the MET and SU cohorts, we excluded people with:
(a) erroneous dates of entering the practice; (b) no history of laboratory
and practice measurements or prescriptions; (c) no recorded HbA1c at
6 months; (d) high serum triglyceride level (>9.0 mmol/mol); (e) an indi-
vidual call rate of single nucleotide polymorphisms (SNPs) < 90%; and
(e) a high leverage point in the multivariate models (Figure 1).
2.2 | Study outcome and covariates
For each of the cohorts, the outcome was HbA1c level at 6 months
after MET or SU treatment. The HbA1c outcome selected was the clos-
est HbA1c measurement to the 6 months after the index date. We
adjusted this outcome by including the HbA1c level at baseline, which
was the latest HbA1c measurement 1 year before or in the first 2 weeks
after index date, as a covariate. This adjustment accounted for the
effect on HbA1c of concurrent treatment at the time of initiation.
To obtain genetic information, DNA was extracted from blood
samples and genotypes were obtained using the iPlex Gold platform
(Agena Bioscience GmbH, Hamburg, Germany) at the Department of
Genetics, University Medical Centre Groningen, the Netherlands. We
then constructed GRSs by summing the number of risk alleles each
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participant had for every SNP and calculated its effect “per GRS unit”
using the established diabetes risk variants representing an individ-
ual's genetic susceptibility risk, as described by Zhou et al.14 We did
not apply a weighted GRS, because of the large heterogeneity among
people with T2DM.
As the primary genetic determinant for the MET and SU cohorts, we
constructed GRSs consisting of SNPs known to be associated with insu-
lin sensitivity (IS-GRS) and β-cell activity (β-GRS), respectively.14 Addi-
tionally, we built another GRS comprising SNPs associated with T2DM
risk (total-GRS), in which the SNPs in the IS-GRS and the β-GRS were
696 participants selected 
377 receiving metformin  
91 receiving SU
10 participants with late intake (2014)
54 participants with no GIANTT data
9 participants who started with other 
drugs 











11 Three combined drugs
5 participants with few prescription 
data 
20 participants with erroneous entry-
to-practice date  
14 participants with no prescriptions 
or measurement history 
49 participants with no HbA1c data at 
end of 6 month-treatment 
289 metformin starters 
70 participants with added 
SU on stable MET dose
6 participants with few prescription 
data 
10 participants with erroneous entry-
to-practice date  
9 participants with no prescriptions 
or measurement history 
1 participant with no record of 
diabetes onset date 
2 participants who started with 
other OADs in 150 days after index 
date 
41 participants with no HbA1c data at 
end of 6-month treatment
92 SU starters282 metformin starters 
3 participants with individual call rate 
<90% 
2 participants with high leverage 
points 
2 participants with high triglyceride 
/ )
89 SU starters 
1 participant with individual call rate 
<90% 
2 participants with high leverage 
points 
2726 people with type 2 diabetes 
approached 
F IGURE 1 Flow diagram of patient selection. GIANTT, Groningen initiative to analyse type 2 diabetes treatment; HbA1c, glycated
haemoglobin; MET, metformin; OAD, oral antidiabetic drug; SU, sulphonylurea derivative
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also included.11 In the genotyping, two SNPs were not present
(rs780094 and rs516946) and no proxy SNP data were available. We
then applied the call rate threshold of 94% and excluded four SNPs.
In the present study, five SNPs from the IS-GRS and 14 from the
β-GRS were present. Both the MET and SU cohorts had a total-GRS
of 59 SNPs, albeit with different compositions (Table S1). All SNPs
included had a minor allele frequency of >0.01 and were in Hardy–
Weinberg equilibrium (P > 10−5).
As clinical covariates, we included baseline age, gender, diabetes
duration, body mass index (BMI), blood pressure and lipid levels (HDL
cholesterol, total cholesterol and triglycerides). With the exception of
BMI, baseline data collection was based on the latest measurement
24 months prior to the index date. To limit missing data, BMI was
measured either as the latest measurement ever or manually calcu-
lated from the latest length measurement and the latest before or the
first measurement of weight 90 days after index date. Age and diabe-
tes duration were calculated from the index date.
2.3 | Statistical analyses
We applied the following statistical analyses to both the MET and SU
cohorts. First, we used a multiple imputation by chained equation pro-
cedure to overcome the missing data. We generated 30 imputed
datasets, the detailed methods for which have been described
previously.15
First, we assessed whether the outcome HbA1c, adjusted for base-
line HbA1c as a covariate, was univariately associated with either the
clinical covariates or GRSs. We then included age, gender and variables
with P values <.20 from the univariate analyses into a multivariate
linear model. Model specification tests (linktest and ovtest functions
in STATA 13; Statacorp, College Station, Texas) were used to assess
whether the variables in the model were correctly defined. In the MET
cohort model, dichotomization of diabetes duration with a 3-month
cut-off point solved the non-linear correlation in the model and
resulted in a balanced number of participants in each category. We also
included a binary HbA1c control status (control being <53 mmol/mol)
at baseline in this model, because the univariate analysis with baseline
HbA1c showed a discontinued slope at 53 mmol/mol. In the SU cohort
model, we included patient status at index date (SU-only or SU-combi)
to correctly specify the model based on linktest and ovtest.
The coefficient of determinant (R2) was used to explain the percent-
age of explained variance and overall performance of the model. The
additional value of genetic covariates was determined by comparing the
explained variance (R2) of models with and without the inclusion
of GRSs.
We conducted complete case analyses for comparison. Further-
more, we determined whether effect modification by the last pre-
scribed dose was present. The last MET dose was defined as the daily
quantity of MET last prescribed in the 6 months after treatment. For
SUs, defined daily dose (DDD) was used to standardize the dose of
different drugs in the same drug class. The last dose for an SU was
thus calculated as daily quantity of SU last prescribed in the 6 months
after treatment, divided by DDD.16
3 | RESULTS
Out of 2726 people with T2DM who were approached, 903 participated
in PROVALID and 696 consented to participate in the genetic study. Of
TABLE 1 Participant characteristics, presented as mean ± SD or
count (percentage)
Characteristics MET SU
Number of participants 282 89
Age at onset, y 59 ± 9 55 ± 9
Age at initiation, y 59 ± 9 58 ± 9
Male gender 167 (59) 56 (62)
Diabetes duration 110 ± 101
0–3 mo 142 (50) -
>3 mo 140 (50) -
Baseline HbA1c, mmol/mol 58.9 ± 14.9 58.7 ± 13.3
HbA1c at 6 mo, mmol/mol 49.2 ± 6.2 49.6 ± 6.7
HbA1c control status, n (%)
<53 mmol/mol 85 (37) -
≥53 mmol/mol 142 (63) -
SU status, n (%)
SU-only - 37 (42)
SU-combi - 52 (58)
Baseline BMI, kg/m2 30.6 ± 5.1 29.5 ± 5.4
Baseline blood pressure, mmHg
Systolic 140.6 ± 18.5 140.5 ± 18.9
Diastolic 83.0 ± 11.8 83.4 ± 11.4
Baseline lipid levels, mmol/L
HDL cholesterol 1.2 ± 0.3 1.2 ± 0.4
Total cholesterol 5.1 ± 1.1 4.7 ± 1.2
Triglycerides 2.1 ± 1.1 2.2 ± 1.3
GRSs
β-cell secretion-related (β-GRS) - 15.2 ± 2.4
Insulin sensitivity-related (IS-GRS) 6.0 ± 1.4 -
Total 71.1 ± 5.6 70.0 ± 5.1
MET dose at 6 mo, n (%)
≤500 mg 117 (41) -
750-1000 mg 95 (34) -
>1000 mg 70 (25) -
SU group, n (%)
Glibenclamide - 1 (1)
Tolbutamide - 27 (30)
Gliclazide - 53 (60)
Glimepiride - 8 (9)
SU dose at 6 mo (DDDs), n (%)
≤0.5 - 50 (56)
>0.5 - 39 (44)
Abbreviations: DDD, defined daily dose; MET, metformin; SU,
sulphonylurea derivatives.
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these 696 participants, 282 initiated MET and 89 initiated SU and met
the inclusion and exclusion criteria for the study (Figure 1). In both the
MET and SU cohorts, the average age of the participants was almost
60 years and ~60% were men. Except for a longer diabetes duration in
the SU cohort, the cohorts had similar clinical characteristics (Table 1).
Based on the univariate analyses (Table S2), diabetes duration and
HbA1c control status at baseline were included in the multivariate model
for the MET cohort. In this model, diabetes duration of >3 months when
initiating MET was associated with a 2.7-mmol/mol higher HbA1c level
after 6 months (Table 2). Not having HbA1c control at baseline was asso-
ciated with an increase of 3.1 mmol/mol in HbA1c level after 6 months,
despite adjustment of the model for baseline level of HbA1c. This multi-
variate model had an explained variance of 22%. The addition of GRSs,
either the IS-GRS or total GRS, showed no improvements in the
explained variance or changes in the β coefficients of the model. The
complete case analysis showed similar results (Table 2).
When stratified by last dose of MET at the end of 6-month treat-
ment (Table S3), the results showed slightly higher explained variance
of the models (R2 = 27%-28%). The effect of diabetes duration was
more prominent when the participants were prescribed <1000 mg
MET daily, while female gender appeared to increase the HbA1c level
in participants prescribed >1000 mg MET daily, with an increase of
4.6 mmol/mol in HbA1c level after 6 months (Table S3). Again, no sig-
nificant effect of adding the IS-GRS was seen in the stratified analysis.
For the SU cohort, no associations were seen in univariate analyses
between the outcome HbA1c and the study covariates (Table S2); thus,
the multivariate model consisted of age, gender and adjustment of SU
patient status (SU-only or SU-combi), showing insignificant associations.
The model had an explained variance of 14%. Similarly to the MET
cohort, the inclusion of either the β-GRS or total GRS in the models had
no effect on the explained variances or β coefficients (Table 3).
4 | DISCUSSION
In the present observational study, we explored the added value of
diabetes-related GRSs in the prediction of HbA1c response after MET
TABLE 2 Multivariate linear regression models for glycated haemoglobin (HbA1c) at 6 mo of metformin treatment, before and after addition
of genetic risk scores (adjusted for HbA1c at baseline)
Variable
Imputed (N = 282)
Without GRS IS-GRS Total GRS
β (95% CI) P β (95% CI) P β (95% CI) P
Female gender 0.47 (−0.90; 1.85) .500 0.48 (−0.90; 1.85) .497 0.46 (−0.92; 1.84) .512
Age (y) −0.04 (−0.12; 0.04) .288 −0.04 (−0.12; 0.04) .306 −0.04 (−0.12; 0.04) .333
Diabetes duration
0-3 mo 0.00 0.00 0.00
>3 mo 2.69 (1.31; 4.07) <.001 2.69 (1.30; 4.06) <.001 2.70 (1.32; 4.08) <.001
HbA1c control status
<53 mmol/mol 0.00
≥53 mmol/mol 3.08 (1.18; 4.98) .002 3.09 (1.18; 4.99) .002 3.09 (1.19; 4.99) .002
IS-GRS/total GRS - - 0.05 (−0.45; 0.55) .849 0.04 (−0.09; 0.15) .586
R2 0.22 0.22 0.22
Variable
Complete case (N = 227)
Without GRS IS-GRS Total GRS
β (95% CI) P β (95% CI) P β (95% CI) P
Female gender 0.49 (−0.87; 1.85) .475 0.49 (−0.87; 1.86) .476 0.49 (−0.87; 1.85) .481
Age (y) −0.03 (−0.10; 0.05) .496 −0.03 (−0.11; 0.05) .490 −0.02 (−0.10; 0.05) .556
Diabetes duration
0-3 mo 0.00 0.00 0.00
>3 mo 2.59 (1.21; 3.97) <.001 2.59 (1.20; 3.97) <.001 2.60 (1.21; 3.98) <.001
HbA1c control status
<53 mmol/mol 0.00
≥53 mmol/mol 3.57 (1.85; 5.28) <.001 3.56 (1.84; 5.28) <.001 3.58 (1.86; 5.30) <.001
IS-GRS/total GRS - - −0.03 (−0.54; 0.48) .903 0.04 (−0.08; 0.16) .542
R2 0.24 0.24 0.24
Abbreviations: CI, confidence interval; GRS, genetic risk score; HbA1c, glycated haemoglobin; IS-GRS, insulin sensitivity GRS.
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and SU initiation. Diabetes duration was shown to be significantly
associated with HbA1c response in a multivariate model of clinical
predictors, which is consistent with previous findings.4,14 No signifi-
cant associations between T2DM-related risk scores and HbA1c
response were observed in univariate and multivariate analyses, either
with mechanism-specific risk genes (IS-GRS and β-GRS) or with risk
genes in general (total-GRS). Moreover, the inclusion of GRSs in the
models did not improve the explained variance.
The genetics of MET or SU treatment response have been studied
previously, and several genetic variants have been identified as being
associated with response to treatment, for instance, in the case of MET
for OCT genes, SLC47A1 and A2 (MATE1 and MATE2), PMAT and ATM,
and in the case of SUs for ABCC8, CYP2C9, KCNJ11, TCF7L2, genes
encoding additional proteins associated with AMP-activated protein
kinase-dependent inhibition of gluconeogenesis, IRS1, NOS1AP.5-8
However, translation into clinical practice of pharmacogenetics is still
lacking. We therefore approached the inter-individual differences in
response to MET and SUs not from the perspective of the genetics in
the context of the drugs, but from the perspective of the genetic varia-
tion in T2DM. We investigated whether part of the inter-individual var-
iability in treatment response to MET and SUs seen in practice could be
explained by possible inter-individual differences, as reflected by the
diabetes risk genes.11 Previously, Hivert et al17 could not detect an
interaction effect of MET on the association of a GRS with T2DM pre-
diction and regression to normal glucose regulation in patients with
impaired glucose tolerance. We investigated a possible effect on
HbA1c in people already diagnosed with T2DM initiating MET or SU
treatment and did not observe any significant associations of the
diabetes-related GRSs in the early stages of the disease. Furthermore,
apart from the total risk genes, we looked at gene clusters specifically
associated with insulin sensitivity and β-cell activity for MET and SUs,
respectively, as related to their mechanism of action, and did not find
any significant effects.
In our observational cohort study we developed a prediction model
for HbA1c levels at 6-month follow-up, adjusted for baseline HbA1c. In
the MET prediction model, a longer diabetes duration and absence of
HbA1c control at the time of treatment initiation resulted in higher
HbA1c levels after 6 months. Neither the total GRS nor the IS-GRS
improved the explained variance of the model. In the SU cohort no sig-
nificant clinical predictors were identified and neither the total GRS nor
the β-GRS improved the explained variance of the model; therefore, in
contrast to the findings of at least some associations between the
genetic makeup and drug response from the perspective of the drug
itself, the T2DM-related GRSs do not seem to be associated with the
variability in HbA1c response in people with T2DM. Risk prediction for
T2DM seems not to coincide with treatment response prediction for
MET and SUs. A more profound analysis of both the pathways of the
drug action and the activity of the molecular pathways within the indi-
vidual patient may lead to better response prediction models.
To our knowledge, this is the first study determining the associa-
tion between diabetes-related GRSs and HbA1c response in people
with T2DM initiating oral glucose-lowering treatment. This observa-
tional study involved a primary care T2DM population, whose medica-
tion data and HbA1c test results were automatically extracted from
medical records through validated procedures. We looked at HbA1c
response after 6 months, which was sufficient to differentiate glucose-
TABLE 3 Multivariate linear regression models for glycated haemoglobin (HbA1c) at 6 mo of sulphonylurea treatment, before and after
addition of genetic risk scores (adjusted for HbA1c at baseline)
Variable
Imputed (N = 89)
Without GRS β-GRS Total GRS
β (95% CI) P β (95% CI) P β (95% CI) P
Female gender 2.45 (−0.40; 5.29) .091 2.35 (−0.58; 5.29) .115 2.47 (−0.38; 5.33) .088
Age (y) −0.01 (−0.17; 0.15) .921 −0.01 (−0.17; 0.16) .925 −0.01 (−0.17; 0.15) .894
SU-combi 2.17 (−0.78; 5.11) .147 2.19 (−0.78; 5.17) .146 2.24 (−0.72; 5.21) .136
β-GRS/GRS - - −0.09 (−0.70; 0.52) .759 −0.10 (−0.37; 0.17) .465
R2 0.14 0.14 0.14
Variable
Complete case (N = 82)
Without GRS β-GRS Total GRS
β (95% CI) P β (95% CI) P β (95% CI) P
Female gender 2.42 (−0.07; 4.90) .056 1.85 (−0.87; 4.58) .180 2.40 (−0.21; 5.01) .071
Age (y) 0.001 (−0.14; 0.14) .988 −0.01 (−0.15; 0.14) .903 −0.02 (−0.16; 0.13) .805
SU-combi 2.85 (0.20; 5.51) .036 3.05 (0.39; 5.71) .025 3.00 (−0.33; 5.66) .028
β-GRS/GRS - - −0.37 (−0.92; 0.18) .181 −0.13 (−0.37; 0.10) .266
R2 0.14 0.16 0.15
Abbreviations: β-GRS, β-cell activity genetic risk score; CI, confidence interval; GRS, genetic risk score; SU-combi, sulphonylurea derivative and metformin
treatment combined.
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regulating responses.15 For this study, 59 SNPs for the total GRS, of
which five were included in the IS-GRS and 14 included in the β-GRS
were studied. We used multiple imputation to overcome missing data
for the covariates. We consider this the optimal approach, but also
conducted complete case analyses, the results of which did not differ
significantly. We were able to include 282 participants in the MET
cohort but only 89 in the SU cohort; therefore, the power to detect
small effects, in particular those related to the SUs, was low. This may
have limited our ability to detect a real effect, particularly if the effect
was small, which is often the case for a disease with a complex under-
lying pathophysiology such as T2DM. We note, however, that we did
not observe a large variance around the GRS which may be the result
of using a GRS instead of individual SNPs.
In conclusion, T2DM-related GRSs in general or specific to the mech-
anism of action of MET and SUs appear not to be predictive for inter-
individual HbA1c variability after initiation of MET and SUs. This study
can be seen as initial indication that the genes implicated in the risk to
T2DM are different from genes associated with response to T2DM
treatment with MET and SUs. Larger studies including more genes are
needed to explain treatment response variability in people with T2DM.
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